Register Free
Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Trial Radar • ClinicalTrials.gov • Registry-linked

Trial Radar

1963 clinical trials with phase, status, specialty and registry links, summarised for rapid clinical review.

1963 recruiting AI clinical summaries
Explore Trial Collections Follow research updates
All Phases Phase I Phase II Phase III Phase IV
Therapeutic Area: All Cardiology / Cardiovascular Dermatology Diabetes / Metabolic Gastroenterology Haematology Infectious Disease Men's Health Mental Health / Psychiatry Nephrology Neurology Oncology Rare Diseases
🔬
Trial Radar

Clinical Trial Intelligence

● Recruiting Phase II
A Study of Brenipatide in Participants With Opioid Use Disorder
Testing whether brenipatide added to buprenorphine treatment improves outcomes for people with opioid addiction compared to placebo.
06 Aug 2026 NCT07420283
● Recruiting Phase II Gastroenterology
Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions
What is being tested: AHB-137 injection is being evaluated as an add-on therapy to existing Nucleos(t)ide Analogue treatment in a phase 2 randomised controlled…
06 Aug 2026 NCT07654283
● Recruiting Phase II Cardiology / Cardiovascular
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
What is being tested: Cemsidomide (a cereblon E3 ligase modulator) combined with dexamethasone in patients with relapsed/refractory multiple myeloma, evaluating its antimyeloma activity, safety,…
06 Aug 2026 NCT07284758
● Recruiting Phase II
Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
Early-stage trial testing whether a new injection drug is safe and well-tolerated in adults with sickle cell disease over 64 weeks.
05 Aug 2026 NCT07224360
● Recruiting Phase I / Phase II Rare Diseases
A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants, Adolescents and Adults With Hearing Loss Due to Otoferlin Mutations
Gene therapy trial testing safety and effectiveness of DB-OTO for hearing loss caused by otoferlin gene mutations in children and adults.
05 Aug 2026 NCT05788536
active not recruiting Phase II Oncology
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
TAPISTRY Trial Summary Study tests tailored cancer drugs matched to individual tumour genetic mutations across multiple cancer types.
05 Aug 2026 NCT04589845
active not recruiting Phase I / Phase II
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
Early-stage trial testing epcoritamab (new antibody) for treatment-resistant B-cell lymphoma, measuring safety, dosing, and effectiveness.
04 Aug 2026 NCT03625037
active not recruiting Phase II Dermatology
A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis
Trial testing lutikizumab injections alone and in combination for moderate to severe eczema over 52 weeks.
04 Aug 2026 NCT06718101
active not recruiting Phase II
An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma
Acalabrutinib showed safety and effectiveness in treating patients with relapsed or refractory mantle cell lymphoma.
04 Aug 2026 NCT02213926
● Recruiting Phase I / Phase II
A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALE1 in Healthy Adults and Adults With Hypophosphatasia in Order to Identify Suitable Doses of ALE1
Early-stage trial testing a new drug (ALE1) for safety and effectiveness in healthy people and those with hypophosphatasia.
03 Aug 2026 NCT07179640
active not recruiting Phase I / Phase II Oncology
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
A radioactive drug combined with standard chemotherapy and immunotherapy is being tested in newly diagnosed extensive small cell lung cancer.
03 Aug 2026 NCT05142696
● Recruiting Phase II Oncology
A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
Intervention: Povetacicept is being tested as a novel treatment for generalized myasthenia gravis (gMG), with evaluation focused on its pharmacodynamic effects, safety profile, and…
03 Aug 2026 NCT07501702
active not recruiting Phase I / Phase II Oncology
A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
Trial testing combined amivantamab and capmatinib drugs in advanced lung cancer with specific genetic mutations to find safe, effective doses.
31 Jul 2026 NCT05488314
● Recruiting Phase II Rheumatology
A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)
Treatment being tested: MK-8690, a novel therapeutic agent, is being evaluated for efficacy and safety in treating moderately to severely active ulcerative colitis, with…
31 Jul 2026 NCT07463183
● Recruiting Phase II Respiratory / COPD / Asthma
Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis
OATD-01 is being tested as a potential therapeutic agent for active pulmonary sarcoidosis in a Phase 2 randomized controlled trial, with assessment of efficacy,…
30 Jul 2026 NCT06205121
● Recruiting Phase II Oncology
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
What is being tested: Subcutaneous zilucoplan, a complement C5 inhibitor, is being evaluated for its pharmacokinetics, safety, tolerability, immunogenicity and clinical activity in pediatric…
30 Jul 2026 NCT06055959
active not recruiting Phase II Oncology
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
Trial testing TAR-200 drug alone or combined with cetrelimab immunotherapy versus cetrelimab alone for bladder cancer resistant to standard treatment.
29 Jul 2026 NCT04640623
active not recruiting Phase I / Phase II
An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias
New drug povetacicept tested in adults with autoimmune blood disorders to assess safety and effectiveness over six months.
28 Jul 2026 NCT05757570
● Recruiting Phase II
A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
Trial testing whether injected Corabotase into head and neck muscles safely and effectively prevents episodic or chronic migraines in adults.
28 Jul 2026 NCT06625060
active not recruiting Phase II
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
Trial testing a new cancer drug (zilovertamab vedotin) alone and combined with other treatments in patients with hard-to-treat B-cell blood cancers.
28 Jul 2026 NCT05458297
● Recruiting Phase II Neurology
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
What is being tested: Remternetug, a potential disease-modifying treatment, is being evaluated for its effectiveness in slowing cognitive decline in asymptomatic individuals at risk…
27 Jul 2026 NCT06647498
● Recruiting Phase II Neurology
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
What is being tested: Investigational disease-modifying treatments in individuals carrying genetic mutations that cause early-onset Alzheimer's disease, with evaluation of biomarker effects, safety, and…
27 Jul 2026 NCT05552157
● Recruiting Phase II Oncology
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
Being Tested: Long-term safety, tolerability, and efficacy of adagrasib (a KRAS G12C inhibitor) as continued treatment in patients with solid tumours, predominantly NSCLC, who…
27 Jul 2026 NCT07415031
● Recruiting Phase II Oncology
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
What is being tested: Plixorafenib (FORE8394), a BRAF inhibitor, is being evaluated for efficacy and safety in patients with locally advanced, metastatic, or recurrent/progressive…
27 Jul 2026 NCT05503797
● Recruiting Phase II Oncology
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
What is being tested: The trial evaluates imzokitug added to pumitamig plus platinum-doublet chemotherapy versus pumitamig plus chemotherapy alone as first-line treatment for locally…
24 Jul 2026 NCT07680764
active not recruiting Phase I / Phase II Oncology
First-in-Human Study of ICT01 in Patients With Advanced Cancer
New antibody drug (ICT01) tested alone and with pembrolizumab in advanced cancer patients to find safe doses and effectiveness.
23 Jul 2026 NCT04243499
active not recruiting Phase II / Phase III
A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy
Zanubrutinib reduced protein in urine in primary membranous nephropathy patients and was compared against standard tacrolimus treatment.
23 Jul 2026 NCT05707377
● Recruiting Phase II Rheumatology
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
Phase 2 trial testing two immunosuppressive drugs in patients with treatment-resistant lupus and rheumatoid arthritis.
23 Jul 2026 NCT06570798
active not recruiting Phase II Dermatology
A Study Evaluating APG777 in Atopic Dermatitis
Trial testing a new drug (APG777) to treat moderate-to-severe eczema, comparing different doses against placebo over 106 weeks.
22 Jul 2026 NCT06395948
active not recruiting Phase II Oncology
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Trial testing two new drugs combined with standard chemotherapy for advanced biliary tract cancer to assess effectiveness and safety.
22 Jul 2026 NCT02711553
● Recruiting Phase I / Phase II Oncology
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Trial testing ubamatamab alone or combined with cemiplimab in recurrent ovarian and other MUC16-positive cancers, assessing safety, dosing, and effectiveness.
22 Jul 2026 NCT03564340
● Recruiting Phase II Oncology
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
What is being tested: Disitamab vedotin (a HER2-targeted antibody-drug conjugate) as monotherapy or in combination with pembrolizumab (PD-L1 inhibitor) for HER2-expressing urothelial cancer, evaluating…
22 Jul 2026 NCT04879329
● Recruiting Phase II
A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis
Delgocitinib cream twice daily reduced symptoms of palmoplantar pustulosis more effectively than placebo cream over 16 weeks.
21 Jul 2026 NCT07013201
● Recruiting Phase II
A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
Trial testing efgartigimod injection versus placebo for systemic sclerosis over 48 weeks to assess safety and effectiveness.
21 Jul 2026 NCT06655155
active not recruiting Phase II Oncology
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Trial testing new drug ABBV-400 combined with chemotherapy and immunotherapy for advanced stomach and gullet cancers.
21 Jul 2026 NCT06628310
active not recruiting Phase II
Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)
Tibulizumab tested against placebo over 24 weeks in systemic sclerosis patients, with all then receiving active drug for 28 weeks.
20 Jul 2026 NCT06843239
active not recruiting Phase I / Phase II
A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration
Single-dose gene therapy injection for wet age-related macular degeneration, with safety and vision outcomes tracked over five years.
16 Jul 2026 NCT06660667
● Recruiting Phase II
A Trial to Compare Treatment With Surlorian (ARM210, S48168) to Placebo in Effects on Muscle Strength and Safety in Adults With Autosomal Dominant RYR1-related Myopathy
Surlorian tested against placebo for improving muscle strength and safety in adults with genetic RYR1-related muscle disease.
15 Jul 2026 NCT07560020
active not recruiting Phase II Oncology
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma
Trial testing whether adding experimental drugs to tislelizumab improves outcomes in advanced head and neck cancer patients.
14 Jul 2026 NCT05909904
active not recruiting Phase I / Phase II Oncology
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers
Early-stage trial testing JNJ-63723283 (anti-PD-1 antibody) to find safe doses and effectiveness across multiple advanced cancers.
14 Jul 2026 NCT02908906
active not recruiting Phase II
Study of INBRX-109 in Conventional Chondrosarcoma
Experimental drug INBRX-109 tested against placebo in patients with advanced chondrosarcoma that cannot be surgically removed.
14 Jul 2026 NCT04950075
● Recruiting Phase I / Phase II Rare Diseases
A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)
LY3884961 (PR001) safety and tolerability study in adults with peripheral Gaucher disease across multiple dose levels over five years.
13 Jul 2026 NCT05487599
● Recruiting Phase II
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
Trial tested whether ianalumab injections could safely improve diffuse cutaneous systemic sclerosis compared to placebo.
10 Jul 2026 NCT06470048
● Recruiting Phase II
EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety
What is being tested: Exaluren, a therapeutic agent designed to enable read-through of nonsense mutations in COL4A3/4/5 genes, is being evaluated in a randomized,…
10 Jul 2026 NCT07523581
● Recruiting Phase II Cardiology / Cardiovascular
Comparative Evaluation of Sustained meChanical AsPiration Thrombectomy and no Thrombus Modification for Pre-stent Thrombus bUrden Reduction in Patients With Acute Myocardial Infarction Study: the CAPTURE AMI Study
Treatment being tested: Sustained mechanical aspiration thrombectomy versus standard percutaneous coronary intervention (PCI) without thrombus modification in STEMI patients with angiographically confirmed high thrombus…
10 Jul 2026 NCT07687576
● Recruiting Phase II Cardiology / Cardiovascular
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
What is being tested: CDR132L, a novel therapeutic agent, is being evaluated at different doses versus placebo to assess its effects on cardiac structure…
09 Jul 2026 NCT06979362
● Recruiting Phase II Oncology
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
What is being tested: Telisotuzumab adizutecan (a novel targeted therapy) combined with standard chemotherapy (oxaliplatin, fluorouracil, folinic acid), bevacizumab, and panitumumab in metastatic colorectal…
09 Jul 2026 NCT06820463
● Recruiting Phase II Oncology
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
What is being tested: Telisotuzumab adizutecan (a novel antibody-drug conjugate targeting HER3) administered intravenously as monotherapy or combined with osimertinib (EGFR tyrosine kinase inhibitor),…
09 Jul 2026 NCT07155187
● Recruiting Phase I / Phase II
A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
Gene therapy trial testing whether a single injection can enable the body to produce its own clotting factor in severe haemophilia B patients.
08 Jul 2026 NCT06379789
active not recruiting Phase I / Phase II
Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma
Testing whether combining vorasidenib with standard chemotherapy is safe and effective for IDH-mutant brain tumours.
08 Jul 2026 NCT06478212